Publicação

Immunotherapy in triple-negative breast cancer: the role of immune checkpoint inhibitors

Ver documento

Detalhes bibliográficos
Resumo:ABSTRACT - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, associated with a poor prognosis in both early and advanced stages. Chemotherapy remains the standard treatment for these patients, despite its limited benefit. Due to the disease’s aggressive features and lack of targeted therapies, several attempts have been made to disclose novel molecular targets. TNBC is now known to be an immunogenic breast cancer subtype. Therefore, immunotherapy has emerged as a promising treatment option for this disease. During the last few years, immune checkpoint inhibitors (anti-PD1/PD-L1 and anti-CTLA-4 monoclonal antibodies) have been investigated either as monotherapy or combined with conventional therapy in TNBC. Herein, we review the status of immunotherapy in TNBC, focusing on the value of immune checkpoint inhibitors.
Autores principais:Branco, Susana
Outros Autores:Graça, Maria Inês; Morais, Sara
Assunto:Triple-negative breast cancer TNBC Immune checkpoint inhibitors ICIs PD-L1 PD-1 CTLA-4 Cancro de mama triplo-negativo Inibidores de checkpoint imunológico
Ano:2022
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Instituto Politécnico de Lisboa
Idioma:inglês
Origem:Repositório Científico do Instituto Politécnico de Lisboa

Registos relacionados

Registos relacionados